Are Medical Stocks Lagging Atea Pharmaceuticals (AVIR) This Year?
Here is how Atea Pharmaceuticals, Inc. (AVIR) and Design Therapeutics, Inc. (DSGN) have performed compared to their sector so far this year.
Zacks
More News
FDA Extends Review Time for AZN's Camizestrant Combo in Breast Cancer
AstraZeneca faces a longer FDA review for camizestrant combo in a certain type of first-line breast cancer after regulators request additional data.
Zacks
AZN, Daiichi's Datroway Wins FDA Nod for Expanded Use in Breast Cancer
AstraZeneca and Daiichi Sankyo get FDA approval for Datroway's expanded use in triple-negative breast cancer treatment.
Zacks
Design Therapeutics Stock Wobbles After Rare Genetic Disease Data
Design Therapeutics reported Phase 1/2 data for DT-216P2, showing biomarker and clinical improvements in Friedreich ataxia patients.read more...
Benzinga
Nasdaq Down 200 Points; Brady Earnings Top Views
US stocks lower as Nasdaq falls 200 points, Dow down 0.04% and S&P 500 down 0.37%. Energy shares up 1.8%, tech stocks down 1.6%. Brady Corp reports strong earnings. Sunshine Biopharma, Virax Biolabs...
Benzinga
Jim Cramer on Design Therapeutics: Pure Spec, Pure Spec
Jim Cramer on Design Therapeutics: Pure Spec, Pure Spec...
Yahoo! Finance: News
Jim Cramer: Design Therapeutics Is 'Pure Spec,' Buy This Health Care Stock
Cramer likes Silicon Motion, whose shares fell 2.2% to settle at $263.85 on Thursday. Wynn shares declined 0.8% to close at $95.43.read more...
Benzinga
Design Therapeutics, Inc. (DSGN) Is Up 6.92% in One Week: What You Should Know
Does Design Therapeutics, Inc. (DSGN) have what it takes to be a top stock pick for momentum investors? Let's find out.
Zacks
Design Therapeutics (NASDAQ:DSGN) Rating Lowered to "Sell" at Wall Street Zen
Wall Street Zen downgraded Design Therapeutics from a "hold" rating to a "sell" rating in a report on Saturday...
MarketBeat
Design Therapeutics (NASDAQ:DSGN) Stock Price Down 13.5% - Should You Sell?
Design Therapeutics (NASDAQ:DSGN) Stock Price Down 13.5% - What's Next...